Georgia Medicaid Mental Health Drugs & Antipsychotics (2026)

Georgia Medicaid mental health drug coverage is broad: antidepressants, antipsychotics, mood stabilizers, and other psychiatric drugs are all covered. But a covered drug can still reject at the pharmacy counter. The drug has to clear the preferred drug list (PDL) that applies to your coverage: your Georgia Families plan's formulary in managed care, otherwise the fee-for-service list of the Georgia Department of Community Health (DCH), which runs Georgia Medicaid. A preferred drug fills with no extra step, while a non-preferred one needs prior authorization (PA) first.

In This Guide

• Key Operative Rules
• How Georgia Medicaid Mental Health Drugs Are Covered (and Why One Rejected)
• How Prior Authorization and Step Therapy Work
• The Mental Health Parity Backstop
• Nursing-Home Antipsychotics and Your Family's Rights
• Which Card Pays If You Have Medicare and Medicaid
• Who Administers Your Pharmacy Benefit in Georgia
• Medications for Substance Use Disorder
• How to Appeal a Denial
• Frequently Asked Questions
• Learn More

Key Operative Rules

How Georgia Medicaid Mental Health Drugs Are Covered (and Why One Rejected)

Georgia Medicaid's drug coverage is built on federal law. Under the Medicaid Drug Rebate Program (Social Security Act Section 1927), manufacturers must pay states a rebate on covered outpatient drugs dispensed to Medicaid beneficiaries.8 The same section limits how far a state can narrow its list: a drug kept off a formulary must still be reachable through prior authorization, and a short list of drugs cannot be excluded from Medicaid coverage at all, benzodiazepines and barbiturates among them.2

What changes whether the drug fills today is the Preferred Drug List. Federal law (Social Security Act Section 1927(d)) lets a state both subject a covered drug to prior authorization and maintain a formulary that steers prescribing, which is the legal basis for a PDL on which non-preferred drugs require PA.2 The PDL is not a closed list: a non-preferred drug is still covered, just with extra administrative steps. What matters in Georgia is which list applies to you, because there is more than one. Georgia's Office of Health Strategy and Coordination has described Georgia Medicaid as four entities providing coverage, the three Georgia Families care management organizations plus the fee-for-service program, "resulting in four different drug lists," and reported that CMOs or their subcontracted pharmacy benefits managers generally prefer to manage their own drug lists. DCH's own managed-care page links a separate drug formulary for each CMO.1 That description comes largely from a January 2023 state study, so confirm the current arrangement with DCH or your plan.

Each plan negotiates its own preferred-drug placement, so the same psychiatric drug can be preferred on one list and need prior authorization on another.1 Confirm any individual drug against the current list for your own coverage.

How Prior Authorization and Step Therapy Work

Prior authorization is the approval a prescriber must obtain before a non-preferred drug is dispensed. The request carries the diagnosis, treatment history, and clinical justification; the plan or its pharmacy benefits manager approves it, denies it, or asks for more.

Two federal protections bound that process, and they are the most actionable facts on this page. Under Social Security Act Section 1927(d)(5), the PA system must provide a response within 24 hours of a request for prior authorization, and it must provide for the dispensing of at least a 72-hour supply of a covered outpatient drug in an emergency situation.2 For psychiatric medication, where an abrupt interruption can be dangerous, that 72-hour supply is worth knowing about, but know its edges. The law writes it as a condition on the state's prior-authorization program rather than as a supply a member can demand on any request; it is triggered by an emergency situation as the Secretary defines it, not by a prior authorization simply running slow, and it does not reach the drugs a state is allowed to exclude or restrict.

Step therapy is the related requirement to try one drug, usually a preferred one, before another is covered. The same federal authority bounds the list rather than simply enabling it. A state may exclude a covered outpatient drug for a specific disease or condition and an identified population only where that drug has no significant, clinically meaningful therapeutic advantage in safety, effectiveness, or clinical outcome over the drugs already on the formulary, and only where a written explanation of the basis for the exclusion is available to the public. A drug kept off the formulary must still be reachable through prior authorization.2

The Mental Health Parity Backstop

If you are in a Georgia Families managed-care plan, federal parity rules limit how much harder the plan can make it to get a psychiatric drug than a comparable medical or surgical one. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) does not require any plan to cover mental-health or substance-use-disorder benefits. What it governs is the terms once a plan does. Financial requirements and treatment limitations on those benefits cannot be more restrictive than the predominant ones applied to substantially all medical and surgical benefits in the same classification, a test run separately across six classifications, prescription drug among them. A non-quantitative limitation such as prior authorization or formulary design is barred unless the processes, evidentiary standards, and factors behind it are comparable to, and applied no more stringently than, those used on the medical side.9 Medicaid is not a group health plan, so MHPAEA does not reach it by its own terms. The standard arrives in Georgia's Medicaid managed care instead through the 2016 Medicaid and CHIP parity final rule (81 FR 18390), which applied MHPAEA to Medicaid managed care organizations, Alternative Benefit Plans, and the Children's Health Insurance Program. That rule has a hard edge: CMS does not apply it to state-plan services for people covered only through fee-for-service, so a fee-for-service member who is not in an Alternative Benefit Plan or CHIP has no federal parity right under it.10

The practical lever for a managed-care family: if your psychiatric drug carries step therapy or a quantity limit that comparable medical drug classes do not, that difference is a parity question the plan must be able to justify. Georgia adds a state layer on top of the federal floor. Georgia's Mental Health Parity Act (House Bill 1013), signed April 4, 2022, added O.C.G.A. Section 33-1-27, which requires every health insurer covering mental health or substance use disorders to provide that coverage in accordance with the federal MHPAEA and, in any medical-necessity, prior-authorization, or utilization-review decision, to apply that Code section's own definitions of generally accepted standards of care and medical necessity. A separate section of the same Act, O.C.G.A. Section 33-21A-13, lays the same duties on every "state health care entity" (the section sits in Georgia's Medicaid Care Management Organizations Act) and is the authority for the mental-health-parity complaint portal DCH runs for Medicaid, PeachCare for Kids, and the State Health Benefit Plan; a complaint about any other plan goes to the Office of Commissioner of Insurance and Safety Fire instead.11

Nursing-Home Antipsychotics and Your Family's Rights

For a loved one in a nursing facility on an antipsychotic for dementia behaviors, the live question is usually not whether Medicaid pays, but whether the drug is a clinically justified treatment or a chemical restraint. Federal rules answer that with specific guardrails.

Two clinical facts frame the decision. Antipsychotic drugs carry an FDA Boxed Warning that older adults with dementia-related psychosis treated with antipsychotics face an increased risk of death. The trial analysis behind the warning, set out in the label, found about 1.6 to 1.7 times the risk of death of patients given a placebo, and the current risperidone label adds, inside that same warning, that risperidone is not approved to treat patients with dementia-related psychosis. The label also reports that observational studies suggest conventional antipsychotics may raise mortality much as the atypicals do, then qualifies it at once: how far that finding is attributable to the drug rather than to something about the patients is not clear.5

Federal rule 42 CFR 483.45 then sets the operating rules inside a Medicaid- or Medicare-certified facility. Each resident's drug regimen must be free of unnecessary drugs, meaning no drug used in excessive dose, for excessive duration, without adequate monitoring, without adequate indication, or in the presence of adverse consequences. "Psychotropic" is broad here: the rule names anti-psychotic, anti-depressant, anti-anxiety, and hypnotic drugs, so these protections reach an antidepressant or a sleeping pill too. A resident not already using psychotropic drugs is not started on one unless it is necessary to treat a specific diagnosed and documented condition; a resident on a psychotropic drug must receive gradual dose reductions and behavioral interventions, unless clinically contraindicated, in an effort to discontinue the drug; an as-needed (PRN) psychotropic order is limited to 14 days, which the prescriber may extend only by documenting the rationale and the duration, while a PRN antipsychotic order cannot be renewed at all without a prescriber re-evaluation; and a licensed pharmacist must review each resident's drug regimen at least once a month, reporting any irregularity, an unnecessary drug included, to the attending physician, the medical director, and the director of nursing. Those reports must be acted upon.6

For a family, those rules translate into the questions worth asking in a care conference:

• What specific diagnosed condition and behavioral target is the drug treating, and is it documented?
• What non-pharmacologic interventions were tried first?
• Has gradual dose reduction been attempted, and if not, why is it clinically contraindicated?
• What monitoring is in place, and was the FDA Boxed Warning discussed before consent?

If those answers are missing, the Georgia Long-Term Care Ombudsman advocates for residents' rights and can investigate and work to resolve a complaint about their care.12

Which Card Pays If You Have Medicare and Medicaid

For a full-benefit dual eligible (someone with both Medicare and full Georgia Medicaid), federal law excludes Part D drugs from Medicaid coverage, so psychiatric prescriptions run through Medicare Part D, not Medicaid pharmacy.3 The card to hand the pharmacist is the Part D card.

Part D gives psychiatric drugs unusually strong protection. Plans must include on their formularies all covered Part D drugs in six classes and categories of clinical concern, set out in Section 1860D-4(b)(3)(G)(iv) of the Social Security Act: antidepressants, antipsychotics, anticonvulsants, immunosuppressants for transplant rejection, antiretrovirals, and antineoplastics. That is not ungated access, and the statute says so on its face: the duty is subject to exceptions the Secretary may establish. Under the 2019 final rule a plan may apply prior authorization or step therapy to a protected-class drug for new starts only, meaning people not already on it, and may do so to steer them toward a preferred alternative rather than only to confirm the indication; those edits are not permitted for antiretrovirals under that exception. Three older exceptions, at 42 CFR 423.120(b)(2)(vi), also stand: a plan may leave a protected-class drug off its formulary where it carries a therapeutic equivalent, apply utilization-management edits for safety, or exclude drugs CMS specifies through a public process. The route past that is the nonformulary appeal, which turns on your prescriber's judgment that no formulary drug for the same condition would be as effective for you or that it would cause adverse effects.4 Benzodiazepines and barbiturates, once excluded from Part D, are now covered for prescriptions dispensed on or after January 1, 2013 under Section 175 of the Medicare Improvements for Patients and Providers Act of 2008 (barbiturates only when used for epilepsy, cancer, or a chronic mental-health disorder).13

Cost is rarely the barrier for a dual eligible. A Medicare beneficiary eligible for full Medicaid is automatically treated as eligible for the Part D Low-Income Subsidy (Extra Help) and does not need to apply. In 2026 the deductible is $0, and copays come in three tiers: $0 for full duals who live in an institution or receive home and community-based services, $1.60 generic or $4.90 brand for full duals with income at or below 100% of the poverty level, and no more than $5.10 generic or $12.65 brand for everyone else on Extra Help. Once out-of-pocket drug costs reach $2,100, covered drugs cost nothing for the rest of the year.7 The standard Part D benefit caps out-of-pocket spending on covered drugs at $2,100 in 2026, after a deductible of no more than $615.14 Georgians with both coverages may also be able to join a Dual Eligible Special Needs Plan (D-SNP), a Medicare Advantage plan type for people with Medicare and Medicaid that must include Part D drug coverage, if one is offered in their area. DCH announced that, to comply with the federal integration rules at 42 CFR 422.514(h), it would place a moratorium on contracting with any new D-SNPs starting August 1, 2025, with further updates to come.15

Who Administers Your Pharmacy Benefit in Georgia

For the fee-for-service population, OptumRx is the pharmacy benefits manager for the Georgia Medicaid fee-for-service outpatient pharmacy program, processing claims at the point of sale. Members in a Georgia Families managed-care plan get their pharmacy benefit through their plan and its own pharmacy benefits manager instead.1

Georgia Families runs three current care management organizations (CMOs): Amerigroup Community Care of Georgia, CareSource Georgia, and Peach State Health Plan.16 DCH links a separate drug formulary for each, and each plan negotiates its own preferred-drug placement, so the tier and prior-authorization rules for a specific psychiatric drug can differ from one plan to the next and from the fee-for-service list.1

Medications for Substance Use Disorder

Georgia's state plan carries the federal Medicaid benefit for medication-assisted treatment of opioid use disorder, which now has no end date and covers drugs approved to treat the disorder, naming methadone, plus the counseling provided with them.17 For buprenorphine, the old prescriber barrier is gone: the Mainstreaming Addiction Treatment (MAT) Act, enacted as Section 1262 of the Consolidated Appropriations Act, 2023, eliminated the former DATA-2000 DEA X-waiver, so any practitioner whose DEA registration includes Schedule III authority may now prescribe buprenorphine for opioid use disorder, if state law permits.18 For naltrexone, and for alcohol use disorder drugs such as acamprosate and disulfiram, check the drug list for your own coverage. Methadone for opioid use disorder may generally be dispensed only through a Substance Abuse and Mental Health Services Administration (SAMHSA)-certified, DEA-registered Opioid Treatment Program (OTP), not at a retail pharmacy or by an office-based prescriber. One carve-out matters for older adults: OTP certification is not required to start or continue methadone treatment for a patient admitted to a DEA-registered hospital or long-term care facility for a medical condition other than opioid use disorder who needs methadone during the stay (42 CFR 8.11(h)(3)).19

How to Appeal a Denial

When a prior authorization is denied, you have appeal rights, and the deadlines are stated in the denial notice itself, so read it as soon as it arrives.

Brevy's Georgia Medicaid appeals and fair hearings guide walks through the process in detail.

Key Contacts for Georgia Medicaid Mental Health Drug Coverage

Learn More

Find personalized help navigating Georgia Medicaid mental health drug coverage at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.